These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 17530704

  • 1. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH.
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [Abstract] [Full Text] [Related]

  • 2. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 3. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M, REAL Study Group.
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [Abstract] [Full Text] [Related]

  • 4. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
    Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG.
    Arthritis Rheum; 2007 Apr; 56(4):1125-33. PubMed ID: 17393394
    [Abstract] [Full Text] [Related]

  • 5. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.
    Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
    [Abstract] [Full Text] [Related]

  • 6. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [Abstract] [Full Text] [Related]

  • 7. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.
    Bernatsky S, Hudson M, Suissa S.
    Rheumatology (Oxford); 2007 Jul; 46(7):1157-60. PubMed ID: 17478469
    [Abstract] [Full Text] [Related]

  • 8. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2008 Feb 15; 59(2):234-40. PubMed ID: 18240258
    [Abstract] [Full Text] [Related]

  • 9. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2004 Jun 15; 50(6):1740-51. PubMed ID: 15188349
    [Abstract] [Full Text] [Related]

  • 10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 11. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 18; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 12. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML.
    Dan Med Bull; 2011 Nov 18; 58(11):B4320. PubMed ID: 22047935
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD.
    Arthritis Rheum; 2011 Mar 18; 63(3):622-32. PubMed ID: 21360491
    [Abstract] [Full Text] [Related]

  • 14. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2007 May 18; 56(5):1433-9. PubMed ID: 17469100
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Jun 18; 54(6):1786-94. PubMed ID: 16736520
    [Abstract] [Full Text] [Related]

  • 16. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.
    J Rheumatol; 2007 Apr 18; 34(4):706-11. PubMed ID: 17309133
    [Abstract] [Full Text] [Related]

  • 17. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.
    Antohe JL, Bili A, Sartorius JA, Kirchner HL, Morris SJ, Dancea S, Wasko MC.
    Arthritis Care Res (Hoboken); 2012 Feb 18; 64(2):215-21. PubMed ID: 21972198
    [Abstract] [Full Text] [Related]

  • 18. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment.
    Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, Frei R, Widmer AF.
    J Rheumatol; 2005 Nov 18; 32(11):2125-9. PubMed ID: 16265689
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
    Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S.
    Arthritis Rheum; 2006 Sep 18; 54(9):2757-64. PubMed ID: 16947774
    [Abstract] [Full Text] [Related]

  • 20. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.
    Ann Rheum Dis; 2013 Jun 18; 72(6):895-900. PubMed ID: 22887849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.